Cemal Cingi1, Arzu Yorgancioglu2, Can Cemal Cingi3, Kıvılcım Oguzulgen4, Nuray Bayar Muluk5, Seçkin Ulusoy6, Nezih Orhon3, Cengiz Yumru7, Dursun Gokdag3, Gul Karakaya8, Şaban Çelebi9, H Bengü Çobanoglu10, Halis Unlu11, Mehmet Akif Aksoy1. 1. ENT Department, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey. 2. Department of Chest Diseases, Medical Faculty, Celal Bayar University, Manisa, Turkey. 3. Faculty of Communication Sciences, Anadolu University, Eskisehir, Turkey. 4. Department of Chest Diseases, Medical Faculty, Gazi University, Ankara, Turkey. 5. ENT Department, Medical Faculty, Kırıkkale University, Kırıkkale, Turkey. 6. ENT Clinic, GOP Taksim Ilkyardım Training and Research Hospital, Istanbul, Turkey. 7. Anaesthesiology Clinic, Taksim Ilkyardım Training and Research Hospital, Istanbul, Turkey. 8. Department of Chest Diseases, Medical Faculty, Hacettepe University, Ankara, Turkey. 9. ENT Clinic, Haseki Training and Research Hospital, Istanbul, Turkey. 10. ENT Clinic, Trabzon Training and Research Hospital, Trabzon, Turkey. 11. ENT Clinic, Ekol ENT Hospital, İzmir, Turkey.
Abstract
BACKGROUND: In this prospective, multicenter, randomized, controlled, double-blind study, we investigated the impact of a mobile patient engagement application on health outcomes and quality of life in allergic rhinitis (AR) and asthma patients. METHODS: In total, 327 patients with diagnoses of persistent AR or mild-to-severe persistent asthma were randomized into 2 intervention groups and 2 control groups upon their admission at outpatient clinics. The intervention groups (POPET-AR and POPET-Asthma) received a mobile phone application ("physician on call patient engagement trial" [POPET]), enabling them to communicate with their physician, and record their health status and medication compliance. The AR groups completed the Rhinitis Quality of Life Questionnaire (RQLQ) at initiation and at the first month of the study. The asthma groups completed the Asthma Control Test (ACT) at initiation and at the third month of the study. RESULTS: The POPET-AR group showed better clinical improvement than the control group in terms of the overall RQLQ score as well in measures of general problems, activity, symptoms other than nose/eye, and emotion domains (p < 0.05). In the POPET-Asthma group, more patients (49%) achieved a well-controlled asthma score (ACT > 19) compared with the control group (27%); this was statistically significant (p < 0.05). CONCLUSION: Use of a mobile engagement platform, such as POPET, can have a significant impact on health outcomes and quality of life in both AR and asthma, potentially decreasing the number of hospital admissions, repeat doctor visits, and losses in productivity. Improvements were seen in domains related to activity, productivity, perception of disease, and emotion.
RCT Entities:
BACKGROUND: In this prospective, multicenter, randomized, controlled, double-blind study, we investigated the impact of a mobile patient engagement application on health outcomes and quality of life in allergic rhinitis (AR) and asthmapatients. METHODS: In total, 327 patients with diagnoses of persistent AR or mild-to-severe persistent asthma were randomized into 2 intervention groups and 2 control groups upon their admission at outpatient clinics. The intervention groups (POPET-AR and POPET-Asthma) received a mobile phone application ("physician on call patient engagement trial" [POPET]), enabling them to communicate with their physician, and record their health status and medication compliance. The AR groups completed the Rhinitis Quality of Life Questionnaire (RQLQ) at initiation and at the first month of the study. The asthma groups completed the Asthma Control Test (ACT) at initiation and at the third month of the study. RESULTS: The POPET-AR group showed better clinical improvement than the control group in terms of the overall RQLQ score as well in measures of general problems, activity, symptoms other than nose/eye, and emotion domains (p < 0.05). In the POPET-Asthma group, more patients (49%) achieved a well-controlled asthma score (ACT > 19) compared with the control group (27%); this was statistically significant (p < 0.05). CONCLUSION: Use of a mobile engagement platform, such as POPET, can have a significant impact on health outcomes and quality of life in both AR and asthma, potentially decreasing the number of hospital admissions, repeat doctor visits, and losses in productivity. Improvements were seen in domains related to activity, productivity, perception of disease, and emotion.
Keywords:
Asthma Control Test (ACT); Rhinitis Quality of Life Questionnaire (RQLQ); allergic rhinitis (AR); asthma; medicine reminders; mobile applications; mobile health; patient communication; patient engagement; physician on call patient engagement trial (POPET)
Authors: Sara Belle Donevant; Robin Dawson Estrada; Joan Marie Culley; Brian Habing; Swann Arp Adams Journal: J Am Med Inform Assoc Date: 2018-10-01 Impact factor: 4.497
Authors: Amy Chan; Anna De Simoni; Vari Wileman; Lois Holliday; Chris J Newby; Claudia Chisari; Sana Ali; Natalee Zhu; Prathima Padakanti; Vasita Pinprachanan; Victoria Ting; Chris J Griffiths Journal: Cochrane Database Syst Rev Date: 2022-06-13
Authors: Chi Yan Hui; Robert Walton; Brian McKinstry; Tracy Jackson; Richard Parker; Hilary Pinnock Journal: J Am Med Inform Assoc Date: 2017-05-01 Impact factor: 4.497
Authors: J Bousquet; G L Onorato; C Bachert; M Barbolini; A Bedbrook; L Bjermer; J Correia de Sousa; N H Chavannes; A A Cruz; E De Manuel Keenoy; P Devillier; J Fonseca; S Hun; T Kostka; P W Hellings; M Illario; J C Ivancevich; D Larenas-Linnemann; J Millot-Keurinck; D Ryan; B Samolinski; A Sheikh; A Yorgancioglu; I Agache; S Arnavielhe; M Bewick; I Annesi-Maesano; J M Anto; K C Bergmann; C Bindslev-Jensen; S Bosnic-Anticevich; J Bouchard; D P Caimmi; P Camargos; G W Canonica; V Cardona; A M Carriazo; C Cingi; E Colgan; A Custovic; R Dahl; P Demoly; G De Vries; W J Fokkens; J F Fontaine; B Gemicioğlu; N Guldemond; Z Gutter; T Haahtela; B Hellqvist-Dahl; E Jares; G Joos; J Just; N Khaltaev; T Keil; L Klimek; M L Kowalski; I Kull; P Kuna; V Kvedariene; D Laune; R Louis; A Magnan; J Malva; E Mathieu-Dupas; E Melén; E Menditto; M Morais-Almeida; R Mösges; J Mullol; R Murray; H Neffen; R O'Hehir; S Palkonen; N G Papadopoulos; G Passalacqua; J L Pépin; F Portejoie; D Price; B Pugin; F Raciborski; F E R Simons; M Sova; O Spranger; C Stellato; A Todo Bom; P V Tomazic; M Triggiani; A Valero; E Valovirta; O VandenPlas; A Valiulis; M van Eerd; M T Ventura; M Wickman; I Young; T Zuberbier; A Zurkuhlen; A Senn Journal: Clin Transl Allergy Date: 2017-10-23 Impact factor: 5.871